Pharmafile Logo

Sylvant

- PMLiVE

Nucleus X Consulting – where patient engagement meets strategic consultancy

Nucleus X Consulting consists of an agile team of specialists that combine expertise in all aspects of patient engagement along with strategic consultancy in rare disease and early-phase medical commercialisation.We...

Nucleus Global

- PMLiVE

Janssen shares new clinical trial data on its psoriasis treatment Tremfya

The results were presented at the 2022 AAD Annual Meeting in March

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Lucid Group Communications Limited

- PMLiVE

Nucleus Global launches Nucleus X Consulting, a specialist consultancy with deep expertise in patient engagement, rare disease, and early-phase medical commercialization

Nucleus Global, the largest specialist medical communications network in the world, announces the launch of a new consultancy to add to its family of agencies. Nucleus X Consulting consists of...

Nucleus Global

Extraordinary lives: advancing change in rare diseases (Part 1)

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. The global rare disease community and its supporters come together on...

Lucid Group Communications Limited

Extraordinary lives: advancing change in rare diseases

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. On this day across the globe, the rare...

Lucid Group Communications Limited

- PMLiVE

Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma

In the study, 98% of patients with relapsed or refractory multiple myeloma responded to a one-off treatment of the drug

- PMLiVE

Rare Disease Day – looking to the future with hope

On this year’s Rare Disease Day, Amanda Henkel, VP, Strategy, Nucleus X Consulting (part of Nucleus Global), reflects on recent advances in the rare disease setting.

Nucleus Global

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

Developing Innovative Digital Strategies to Engage Patients

Caitlin Wagner, Associate Marketing Director at Pharming, shares her expertise on innovative patient engagement strategies, including the roles of mobile apps and social media, the impact of the COVID-19 pandemic...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links